Equity Details
Price & Market Data
Price: $2.80
Daily Change: +$0.01 / 0.36%
Daily Range: $2.71 - $2.94
Market Cap: $535,657,056
Daily Volume: 4,826,666
Performance Metrics
1 Week: 1.41%
1 Month: 2.87%
3 Months: 75.00%
6 Months: 117.4%
1 Year: 850.3%
YTD: 76.07%
About Ovid Therapeutics Inc. (OVID)
Uncover the latest on Ovid Therapeutics Inc. (OVID). Trading at 2.80, the stock has shown a daily change of +$0.01 / 0.36%. With a market cap of 535,657,056, its performance over the last week (1.41%) and month (2.87%) provides key insights.
Company Details
Employees: 23
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and infant drug-resistant epilepsies; and OV4071, a first-in-human oral potassium-chloride cotransporter 2 direct activator which is in Phase 1 clinical trials for the treatment of psychosis associated with parkinson's disease, lewy body dementia, and acute schizophrenia. It has license and collaboration agreements with AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.